CSIMarket
 
Htg Molecular Diagnostics Inc  (HTGM)
Other Ticker:  
 
 
Price: $0.4800 $-0.12 -20.000%
Day's High: $0.6099 Week Perf: -44.83 %
Day's Low: $ 0.46 30 Day Perf: -81.65 %
Volume (M): 773 52 Wk High: $ 4.77
Volume (M$): $ 371 52 Wk Avg: $2.49
Open: $0.57 52 Wk Low: $0.46



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 0

Htg Molecular Diagnostics Inc
HTG Molecular Diagnostics Inc is a biotechnology company that specializes in developing and providing molecular diagnostic solutions. The company focuses on creating platforms and assays for gene expression profiling, miRNA analysis, and next-generation sequencing. They offer products and services to research institutions, pharmaceutical companies, and clinical laboratories for various applications in precision medicine, translational research, and molecular diagnostics. HTG Molecular Diagnostics aims to enable healthcare providers to make more informed treatment decisions by offering accurate and reliable molecular testing solutions.


   Company Address: 3430 E. Global Loop Tucson 85706 AZ
   Company Phone Number: 289-2615   Stock Exchange / Ticker: NASDAQ HTGM
   HTGM is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Htg Molecular Diagnostics Inc

Deficit on Weak Sales Plagues HTG Molecular Diagnostics Inc. during Q1 2023

Investors in Htg Molecular Diagnostics Inc. (HTGM) have been left disappointed by the company's financial first quarter results for 2023, which have been decidedly bearish. The company has reported a deficit per share of $-2.28, a significant increase from the $-0.81 per share deficit that was reported a year ago. Even more worrying is that this represents a surge in deficit from the preceding quarter, which saw a $-0.43 per share deficit.
The financial first quarter of 2023 has been difficult for Htg Molecular Diagnostics Inc. with revenue declining by a respectable -12.828% to just $1.03 million, down from $1.18 million in the corresponding quarter a year ago. This is a worrying trend for investors as the sequentially revenue tumbled by -57.672% from $2.44 million.






 

Htg Molecular Diagnostics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com